TQB2102

TQB2102 for injection is a novel antibody-coupled drug (ADC) that enhances binding to tumor cell surface HER2 proteins by simultaneously targeting the two non-overlapping epitopes of the HER2 protein, Endothelial Cell Dysfunction 2 (ECD2) and Endothelial Cell Dysfunction 4 (ECD4), increasing HER2 internalization, and then down-regulating the tumor cell surface HER2 proteins more effectively, and doubly blocking the HER2 signaling, to achieve the effects of trastuzumab and Pertuzumab alone and in combination. This is a Phase II study to evaluate the efficacy and safety of TQB2102 for injection in combination with Benmelstobart Injection /Penpulimab Injection ± capecitabine in patients with unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma

主要目的： 评价注射用TQB2102联合贝莫苏拜单抗/派安普利单抗±卡培他滨在不可切除的局部晚期、复发性或转移性HER2阳性胃食管腺癌中的有效性。 次要目的： 评价注射用TQB2102联合贝莫苏拜单抗/派安普利单抗±卡培他滨在不可切除的局部晚期、复发性或转移性HER2阳性胃食管腺癌中的安全性； 探索性目的： 评价注射用TQB2102在不可切除的局部晚期、复发性或转移性HER2阳性胃食管腺癌的药代动力学（PK）特征和免疫原性； 与疗效、作用机制、安全性和/或病理机制相关的生物标志物研究。